Search research articles
Contact Us
Filters
Showing results (171-180 of 189) with videos related to
Page
of 19
Sort By:
BMJ (Clinical Research Ed.)
|
December 3, 1988
Abnormal electromyographic activity of the urethral sphincter, voiding dysfunction, and polycystic ovaries: a new syndrome?
C J Fowler, T J Christmas, C R Chapple, et al.
Archives of Pathology & Laboratory Medicine
|
March 1, 1988
Xanthogranulomatous pyelonephritis. A reappraisal and immunohistochemical study
G N Antonakopoulos, C R Chapple, J Newman, et al.
Archives of Pathology & Laboratory Medicine
|
February 1, 1986
Ectopic beta-human chorionic gonadotropin production by bladder urothelial neoplasia
V M Shah, J Newman, J Crocker, et al.
British Journal of Urology
|
October 17, 1998
The value of prostate specific antigen (PSA) density and free: total PSA ratio in selecting patients with a normal digital rectal examination and intermediate total PSA levels for further investigation
H C Klingler, H Woo, D Rosario, et al.
International Journal of Clinical Practice
|
April 8, 2014
Safety and tolerability of the β3 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial
V W Nitti, C R Chapple, C Walters, et al.
Lancet (London, England)
|
June 25, 1988
A new treatment for urethral strictures
E J Milroy, C R Chapple, J E Cooper, et al.
European Urology
|
November 30, 2005
Medical consumption and costs during a one-year follow-up of patients with LUTS suggestive of BPH in six european countries: report of the TRIUMPH study
N J A van Exel, M A Koopmanschap, J McDonnell, et al.
International Journal of Clinical Practice
|
June 29, 2010
Assessing patients' descriptions of lower urinary tract symptoms (LUTS) and perspectives on treatment outcomes: results of qualitative research
K S Coyne, C C Sexton, Z Kopp, et al.
European Urology
|
July 2, 2005
A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial
C R Chapple, R Martinez-Garcia, L Selvaggi, et al.
Lancet (London, England)
|
December 24, 1988
Role of subcutaneous apomorphine in parkinsonian voiding dysfunction
T J Christmas, P A Kempster, C R Chapple, et al.
Page
of 19
Search research articles
Search
Showing results (171-180 of 189) with videos related to
Sort By:
Page
of 19
BMJ (Clinical Research Ed.)
|
December 3, 1988
Abnormal electromyographic activity of the urethral sphincter, voiding dysfunction, and polycystic ovaries: a new syndrome?
C J Fowler, T J Christmas, C R Chapple, et al.
Archives of Pathology & Laboratory Medicine
|
March 1, 1988
Xanthogranulomatous pyelonephritis. A reappraisal and immunohistochemical study
G N Antonakopoulos, C R Chapple, J Newman, et al.
Archives of Pathology & Laboratory Medicine
|
February 1, 1986
Ectopic beta-human chorionic gonadotropin production by bladder urothelial neoplasia
V M Shah, J Newman, J Crocker, et al.
British Journal of Urology
|
October 17, 1998
The value of prostate specific antigen (PSA) density and free: total PSA ratio in selecting patients with a normal digital rectal examination and intermediate total PSA levels for further investigation
H C Klingler, H Woo, D Rosario, et al.
International Journal of Clinical Practice
|
April 8, 2014
Safety and tolerability of the β3 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial
V W Nitti, C R Chapple, C Walters, et al.
Lancet (London, England)
|
June 25, 1988
A new treatment for urethral strictures
E J Milroy, C R Chapple, J E Cooper, et al.
European Urology
|
November 30, 2005
Medical consumption and costs during a one-year follow-up of patients with LUTS suggestive of BPH in six european countries: report of the TRIUMPH study
N J A van Exel, M A Koopmanschap, J McDonnell, et al.
International Journal of Clinical Practice
|
June 29, 2010
Assessing patients' descriptions of lower urinary tract symptoms (LUTS) and perspectives on treatment outcomes: results of qualitative research
K S Coyne, C C Sexton, Z Kopp, et al.
European Urology
|
July 2, 2005
A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial
C R Chapple, R Martinez-Garcia, L Selvaggi, et al.
Lancet (London, England)
|
December 24, 1988
Role of subcutaneous apomorphine in parkinsonian voiding dysfunction
T J Christmas, P A Kempster, C R Chapple, et al.
Page
of 19